Can a Mistranslated PIL Trigger an EMA Variation or Recall
- 1 hour ago
- 6 min read
Yes. A wrong word in a translated package leaflet can force a variation, and in the worst case a batch recall, because the leaflet is part of the marketing authorisation, not decoration on the box.
The package leaflet, the PIL, is the folded sheet inside every medicine pack. Under Directive 2001/83/EC Article 59, its content is approved together with the summary of product characteristics when the marketing authorisation is granted. Article 63(1) then requires that leaflet to appear in the official language or languages of each member state where the medicine is placed on the market. A German leaflet, a Finnish leaflet, and a Portuguese leaflet are three separate approved documents that all have to say the same thing.
Why the leaflet is a regulated document, not packaging copy
Regulatory teams sometimes treat translation as the last cosmetic step before print. It isn't. The version the competent authority approves is the version you're legally bound to distribute. When a translated leaflet drifts from the approved source, that national version stops matching the authorisation, and the mismatch is a finding waiting to be raised at the next review.
The leaflet is also derived from the SmPC, so upstream edits flow down. One SmPC change can cascade into retranslation across every language version, and each cascade is another chance for one line to diverge. That is why we at AD VERBUM see leaflet errors cluster on safety-critical fields, where the English source was correct and signed off, yet a single localised line reads differently from what the assessor approved.
The errors that carry real weight
Not every typo is a safety event. The fields that turn a translation slip into a regulatory problem are the ones that change what a patient does:
Dosing. A decimal point that moves, or “once daily” rendered as “twice daily,” changes the dose a patient takes.
Contraindications. A dropped “not” or an omitted patient group can tell someone the medicine is safe for them when it is not.
Warnings and precautions. Softened wording on driving, alcohol, or pregnancy removes a caution the assessor required.
Interactions and overdose instructions. A vague verb changes what a patient does in an emergency.
Each maps to a section fixed by the QRD template, the EMA Quality Review of Documents format that standardises leaflet headings and much of the wording. Off-template phrasing reads as a deviation, and a safety-relevant deviation reads as a risk.
How the error gets found
Two checks catch most of it before print, and both are formal. Before a marketing authorisation is granted, Article 61(1) requires mock-ups of the packaging and the draft leaflet to go to the competent authority. Article 59(3) requires the leaflet to reflect consultations with target patient groups, the readability or user-testing step.
The EU readability guideline sets the bar plainly. A leaflet passes when 90% of a test group can find the key information and, of those who find it, 90% can understand it and act on it. A mistranslation that makes a warning unfindable or ambiguous fails that test in the target language even when the English passed. After launch, the same errors surface through national competent authority review of a variation, through a pharmacovigilance signal, or through a patient or pharmacist complaint.
The escalation path: variation, then worse
Correcting an approved leaflet is not a quiet edit. Any change to the product information runs through a variation under Regulation (EC) No 1234/2008, so even a clean fix means a submission, assessment, and updated approved text across every affected language. The coordination discipline is the same one you need to coordinate PSUR translation before an EMA deadline.
When the error touches safety, the path gets steeper. Directive 2001/83/EC Article 116 lets a competent authority vary, suspend, or revoke a marketing authorisation where the product information is incorrect, and Article 117 lets it prohibit supply and order the product withdrawn from the market. A contraindication missing from one national leaflet can trigger an urgent safety restriction and a recall of the affected batches in that market, at the marketing authorisation holder's cost and on the public record.
What to control before the leaflet ships
Divergence is preventable. The controls that keep two dozen language versions saying one thing are process, not luck:
Lock the source. Freeze the approved English version and translate from that one locked file, never from a working draft that is still moving.
Run a governed term base. Contraindication names, dosing units, and warning phrases carry across languages and across variation cycles from one controlled glossary, not per-translator memory.
Back-translate the safety fields. Dosing, contraindications, and warnings get an independent back-translation and reconciliation, so a reversed meaning is caught before submission.
Keep an independent second reviewer. A qualified reviewer who did not do the translation checks each language against the source and the QRD template.
This is where AD VERBUM does the work that keeps a leaflet defensible, the same rigor we bring to EMA pharma regulatory translation across the product-information lifecycle. Our ISO 17100 certified process builds in an independent second-linguist revision on every project, so no safety field ships on one person's reading. We run pharma terminology from a governed term base, review through subject-matter linguists who know SmPC and leaflet conventions, and host the whole workflow on EU-based, ISO 27001 certified infrastructure. Where machine translation feeds a first draft, our ISO 18587 post-editing keeps a certified human in control of the wording a patient will read.
Our pharmaceutical translation services
Our translation services for regulated sectors run on ISO 27001 and ISO 42001 certified, EU-hosted infrastructure, with no reliance on public cloud tooling for core processing. Every project runs through our AI+HUMAN hybrid workflow: we ingest client Translation Memories and Term Bases first, our proprietary LLM-based LangOps System generates output constrained by client terminology on client-tuned open-weight models, and our certified subject-matter experts review for technical accuracy and regulatory compliance. Our QA is aligned to ISO 17100 and ISO 18587, with sector-specific requirements such as the EU product-information rules under Directive 2001/83/EC and Regulation (EC) No 1234/2008 variations applied where relevant. We serve Life Sciences, Legal, Finance, Defense, and Manufacturing clients across 150+ languages with 3,500+ subject-matter linguists. For teams managing audit-sensitive content, contact us to discuss your security and compliance requirements directly.
FAQ
Is the package leaflet part of the marketing authorisation?
Yes. Under Directive 2001/83/EC Article 59, the package leaflet is approved as part of the product information alongside the summary of product characteristics. The version the competent authority approves is the version you must distribute, so a translated leaflet that diverges no longer matches the authorisation.
Which leaflet errors are most likely to trigger regulatory action?
Errors in dosing, contraindications, warnings, and overdose instructions carry the most weight, because they change what a patient does. A moved decimal or a dropped “not” in a contraindication is a safety issue, not a stylistic one, and these are the fields the QRD template and readability testing scrutinise.
Does fixing a leaflet translation require a variation?
Yes. Any change to approved product information, including a translation correction, runs through a variation under Regulation (EC) No 1234/2008. Even a straightforward fix means a submission, assessment, and an updated approved text in every affected language version.
Can a mistranslation actually cause a recall?
It can. Directive 2001/83/EC Article 116 allows a competent authority to suspend or revoke a marketing authorisation when the product information is incorrect, and Article 117 allows it to prohibit supply and order a market withdrawal. A safety-relevant leaflet error can lead to an urgent safety restriction and a recall of affected batches.
What is readability or user testing and how does it catch translation errors?
Article 59(3) requires the leaflet to reflect consultations with target patient groups. The EU readability guideline sets the benchmark: 90% of a test group should find the key information and 90% of those should understand and act on it. A mistranslation that makes a warning unfindable or ambiguous fails that test in the target language.
How does AD VERBUM prevent leaflet translation errors?
We lock the approved source, run a governed term base, back-translate the safety-critical fields, and apply an independent ISO 17100 second-linguist revision on every project. The workflow runs on EU-hosted, ISO 27001 certified infrastructure, with ISO 18587 post-editing wherever machine translation feeds a draft.
